Del Rosso James Q, Lain Edward, York Jean Philippe, Alexis Andrew
JDR Dermatology Research/Thomas Dermatology, Las Vegas, NV, USA.
Advanced Dermatology and Cosmetic Surgery, Maitland, FL, USA.
Dermatol Ther (Heidelb). 2022 Sep;12(9):2189-2200. doi: 10.1007/s13555-022-00788-w. Epub 2022 Aug 22.
The clinical appearance of acne vulgaris (AV) and the response to therapeutic agents may vary in people with skin of color (SoC) compared with those with lighter skin types. Given the heightened potential for postinflammatory hyperpigmentation and keloid development, effective and timely AV treatment in patients with SoC is especially important. However, these patients are frequently underrepresented in clinical trials, and SoC photographs are generally underrepresented in dermatology. Trifarotene 0.005% cream is a retinoid approved for the once-daily topical treatment of AV, and was studied in large-scale clinical trials that assessed the treatment of AV on both the face and trunk. For severe AV, a topical retinoid may be used in combination with an oral antibiotic, such as doxycycline. Five subjects covering Fitzpatrick skin phototypes III, IV, V, and VI were selected from two larger studies to visually demonstrate treatment of clinically diagnosed AV with trifarotene 0.005% cream. Two subjects received 24 weeks of treatment with trifarotene 0.005% cream for moderate AV on the face and trunk, while three subjects received 12 weeks of treatment with trifarotene 0.005% cream in association with 120 mg oral doxycycline with modified polymer coating for severe facial AV. This case series supports the favorable efficacy and safety of facial and truncal AV treatment with trifarotene 0.005% cream, with or without oral doxycycline, in subjects with SoC (phototypes III-VI).
与肤色较浅的人群相比，寻常痤疮（AV）在有色人种（SoC）中的临床表现及对治疗药物的反应可能有所不同。鉴于有色人种发生炎症后色素沉着和瘢痕疙瘩的可能性更高，对其进行有效且及时的寻常痤疮治疗尤为重要。然而，这些患者在临床试验中的代表性往往不足，而且在皮肤病学领域，有色人种的照片通常也较少。0.005%的曲法罗汀乳膏是一种已获批准用于每日一次局部治疗寻常痤疮的维甲酸类药物，曾在评估其对面部和躯干寻常痤疮治疗效果的大规模临床试验中进行研究。对于重度寻常痤疮，可将局部维甲酸类药物与口服抗生素（如强力霉素）联合使用。从两项规模更大的研究中选取了5名涵盖Fitzpatrick皮肤光类型III、IV、V和VI的受试者，以直观展示0.005%曲法罗汀乳膏对临床诊断的寻常痤疮的治疗效果。两名受试者接受了为期24周的0.005%曲法罗汀乳膏治疗，用于治疗面部和躯干的中度寻常痤疮，而三名受试者接受了为期12周的0.005%曲法罗汀乳膏联合120mg口服改良聚合物包衣强力霉素的治疗，用于治疗重度面部寻常痤疮。该病例系列支持了在有色人种（光类型III - VI）受试者中，无论是否联合口服强力霉素，使用0.005%曲法罗汀乳膏治疗面部和躯干寻常痤疮具有良好的疗效和安全性。
